- Home
- SPRO vs HQI Comparison
SPRO vs HQI Comparison
Compare SPRO & HQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- HQI
- Stock Information
- Founded
- SPRO 2013
- HQI 2002
- Country
- SPRO United States
- HQI United States
- Employees
- SPRO N/A
- HQI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- HQI Professional Services
- Sector
- SPRO Health Care
- HQI Consumer Discretionary
- Exchange
- SPRO Nasdaq
- HQI Nasdaq
- Market Cap
- SPRO 128.9M
- HQI 140.2M
- IPO Year
- SPRO 2017
- HQI N/A
- Fundamental
- Price
- SPRO $2.36
- HQI $8.56
- Analyst Decision
- SPRO Buy
- HQI Buy
- Analyst Count
- SPRO 4
- HQI 1
- Target Price
- SPRO $5.00
- HQI $13.00
- AVG Volume (30 Days)
- SPRO 1.2M
- HQI 13.2K
- Earning Date
- SPRO 11-13-2025
- HQI 11-06-2025
- Dividend Yield
- SPRO N/A
- HQI 2.80%
- EPS Growth
- SPRO N/A
- HQI N/A
- EPS
- SPRO N/A
- HQI 0.17
- Revenue
- SPRO $48,576,000.00
- HQI $32,610,000.00
- Revenue This Year
- SPRO N/A
- HQI N/A
- Revenue Next Year
- SPRO N/A
- HQI $1.38
- P/E Ratio
- SPRO N/A
- HQI $49.04
- Revenue Growth
- SPRO N/A
- HQI N/A
- 52 Week Low
- SPRO $0.51
- HQI $8.04
- 52 Week High
- SPRO $3.22
- HQI $15.75
- Technical
- Relative Strength Index (RSI)
- SPRO 57.47
- HQI 42.39
- Support Level
- SPRO $2.16
- HQI $8.25
- Resistance Level
- SPRO $2.44
- HQI $8.96
- Average True Range (ATR)
- SPRO 0.12
- HQI 0.40
- MACD
- SPRO -0.00
- HQI 0.02
- Stochastic Oscillator
- SPRO 55.24
- HQI 53.06
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.